New research reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt traditional lifestyle regimens.
Published data in a leading medical journal demonstrates that while overweight people often shed a large proportion of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these drugs should be informed of the potential of rapid rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
Such speed of regain means a return to original mass within about a year and a half.
Comparing Approaches
The research, which looked at dozens of trials involving thousands of patients, compared the results of the injectable medications with other pills.
The team note that individuals who lose weight through dieting usually experience a more gradual weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Nutrition scientists suggest the mechanism of the drugs accounts for the heightened rebound.
The injections mimic a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of the hormone levels several times higher than normal might result in the body to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the high risk of relapse, the treatment might need to be ongoing.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the chronic character of obesity," similar to managing diseases like diabetes.
User Experiences
Users who have stopped the medication explain a powerful return of appetite.
"It felt as if a trigger activating and you become ravenous," recalled an individual.
This challenge is worsened if users have not established sustainable dietary or behavioural modifications during treatment.
Growing Use
Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with desire remaining high.
- Adoption is more common among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and long-term success relies on combined lifestyle support.
